What is Telomir Pharmaceuticals, Inc. Common Stock?
, a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 36.15M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.